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A B S T R A C T
Background: In January 2020 reports of unidentified severe respiratory illness were described in Wuhan, China.
A rapid expansion in cases affecting most countries around the globe led to major changes in the way people live
their daily lives. In the United Kingdom, the Department of Health and Social Care directed healthcare providers
to establish additional resources to manage the anticipated surge in cases that could overwhelm the health
services. A priority area was testing for SARS-CoV-2 RNA and its detection by qualitative RT-PCR.
Design: A laboratory workflow twinning research environment with clinical laboratory capabilities was im-
plemented and validated in the University of Birmingham within 4 days of the project initiation. The diagnostic
capability was centred on an IVD CE-marked RT-PCR kit and designed to provide surge capacity to the nearby
Queen Elizabeth Hospital. The service was initially tasked with testing healthcare workers (HCW) using throat
swabs, and subsequently the process investigated the utility of using saliva as an alternative sample type.
Results: Between the 8th April 2020 and the 30th April 2020, the laboratory tested a total of 1282 HCW for
SARS-CoV-2 RNA in throat swabs. RNA was detected in 54 % of those who reported symptoms compatible with
COVID-19, but in only 4% who were asymptomatic.
Conclusion: This capability was established rapidly and utilised a cold-chain free methodology, applicable to a
wide range of settings, and which can provide surge capacity and support to clinical laboratories facing in-
creasing pressure during periods of national crisis.
1. Background
SARS-CoV-2 is an emerging sarbecovirus, closely related to SARS-
CoV-1 that emerged in China in 2004 [1]. This new strain was first
described in January 2020 as a cause of a novel severe respiratory ill-
ness now known as COVID-19. As of the 3rd May 3,356,205 confirmed
cases were reported globally with 238,730 deaths, affecting 215
countries around the world [2]. The rapid development of the pan-
demic highlights the need to speedily assemble the capability to support
healthcare services in a variety of international settings. Responsive
capacity building was part of the United Kingdom’s strategy to rapidly
scale up testing for SARS-CoV-2 RNA in respiratory samples using qRT-
PCR. A directive from the Department of Health and Social Care, and
National Health Service Improvement (NHSI) instructed NHS hospitals
to identify the means to increase testing capacity [3]. Accordingly, the
University of Birmingham (UoB) was included in an extended labora-
tory network to provide additional capacity to the existing diagnostic
laboratories in the West Midlands region, particularly to support
healthcare worker testing. Rapid technology and knowledge transfer
combined with a partnership between a UKAS-accredited clinical ser-
vice and academic research infrastructure reconfigured the laboratories
into a molecular diagnostic service capable of providing quality assured
testing using a verified commercial test. External support was provided
by Public Health England clinical virologists in an advisory role.
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This manuscript describes the rapid implementation and validation
of the process to support healthcare worker testing in the West
Midlands at the University of Birmingham.
2. Study design and materials
Initially, 120 specimens were tested by both the SARS-CoV-2 testing
process at the University and at the Queen Elizabeth Hospital to verify
the assay and validate the diagnostic process. This total consisted of 94
residual RNA extracts anonymised at source, and 26 respiratory swabs
collected from in-patients giving informed consent to provide 2 swabs
to assist with improving diagnostics.
Secondly, a total of 1283 nose & throat swabs were collected from
volunteer healthcare workers (HCW) giving informed consent for their
samples to be tested for SARS-2-CoV. Of these, 258 specimens were self-
taken, and 1025 collected by research nurses in the Institute of
Translational Medicine.
Samples were received and logged at Containment Level 2 (CL-2)
before safe transfer to Advisory Committee on Dangerous Pathogens
(ACDP) Containment Level 3 (CL-3) facilities, where sample inactiva-
tion [5] was performed with buffer ATL (Qiagen). Samples were pro-
cessed further at CL-2 using the RNEasy Mini Kit reagents (Qiagen).
qRT-PCR testing for SARS-CoV-2 RNA was performed using the
VIASURE qRT-PCR detection test for SARS-CoV-2 (CerTest; Prolabs).
The VIASURE test is a multiplex of three targets: the viral N and
ORF1ab genes (China-CDC) [4], and a synthetic internal control to
detect assay inhibition. Lyophilized reaction reagents were recon-
stituted, 15 μl of master mix used per reaction with the addition of 5 μl
sample RNA. Thermocycling was performed on either ABI 7500 or
QuantStudio 5 instruments. All preliminary data analysis from qRT-PCR
analyses was performed using the Thermo Cloud software (Thermo
Scientific), with automated threshold and baseline setting followed by
careful manual inspection of individual amplification curves by two
senior experienced operators. Final interpretation of the RT-PCR assay
results was as specified in the manufacturer instructions for use (IFU).
Confirmatory testing on indeterminate results was performed with E
gene assay [4]. These results were transmitted electronically to the
UKAS-accredited service, for reporting to the NHS Trust and Public
Health England surveillance systems.
3. Study results
To investigate the analytical sensitivity of the VIASURE qRT-PCR, it
was compared to the analytical sensitivity of the SARS-2-CoV ‘E’ gene
assay described by the WHO [4], and which is a more widely
characterised tests (Table 1). The VIASURE Orf1ab detection appears to
be an estimated 10-fold less sensitive than the E gene assay, but 10-fold
more sensitive than the RdRp gene. The VIASURE N gene assay ap-
peared to be of comparable sensitivity to the RdRp gene target (Fig. 1).
Comparative testing against other validated assays was performed
using in-house control material derived from pooled patient specimens
where RNA from SARS-CoV-2 had been detected. Samples were tested
on WHO RdRp and E gene assays in parallel with the VIASURE qRT-
PCR assay. The mean Ct value obtained with the E gene (WHO), the N
gene and Orf1ab gene assays (VIASURE) were not significantly different
by repeated measures ANOVA. However, analysis demonstrated that
RdRp was significantly different from E gene, N-gene and Orf1ab gene
(p=<0.0001), with an average deviation in Ct value of +5.4 Ct, in-
dicating a significant difference in assay sensitivity (Fig. 2).
Gaining experience of qRT-PCR testing and reproducibility of the
workflow was initially assessed by testing (a) a panel of residual RNA
preparations from the Queen Elizabeth Hospital which had been ex-
tracted and previously tested on the Altona commercial qRT-PCR assay
(n = 94) or (b) original respiratory samples collected from patients the
same day and tested on an Abbott m2000 commercial qRT-PCR assay (n
= 26). Results of these comparisons are shown in Table 2. The Ct values
obtained for each assay were analysed by Pearson correlation analysis
in a pairwise fashion, indicating a strong correlation in all comparisons
(R2 =>0.88; Fig. 3).
In the comparison of the 94 RNA extracts tested by VIASURE and
Altona, the majority of positive and negative results agreed between the
two tests. Importantly, there were no Altona positive results that were
found negative by VIASURE. Three Altona negative samples had equi-
vocal results on VIASURE, where the ORF1ab target was negative but N
gene target detected at Ct< 38; albeit still relative high Cts (at 36, 33,
and 36).
In the second analysis of 26 clinical samples, the end-to-end process
of testing from fresh respiratory specimens was compared with that at
QEH. By coincidence, the QEH Pathology testing method had changed
from Altona to Abbott m2000, an assay which has acknowledged
greater analytical sensitivity than the Altona. Nevertheless, the results
of the direct comparison showed that there was 100 % concordance
between positive and negative results obtained by VIASURE and the
Abbott test (Table 2). Combining the results and experience of per-
forming the VIASURE test in a full diagnostic process, with further
adjustments to reduce the chances of contamination, the VIASURE test
was considered as verified for use.
Accordingly, the VIASURE test was utilized in the analysis of
symptomatic and asymptomatic HCW. Throat swab samples were taken
from 1283 subjects and tested between the 8th April and the 30th April,
Table 1
Relative analytical sensitivity between the VIASURE qRT-PCR assay (Orf1ab and N gene) and the WHO E gene and RdRp assay. Proportion of replicates detection in a
10 fold linear dilution series from 10e-1 to 10e-8, the mean Ct value obtained for each dilution in each of the assays tested is also given. N.D. denotes Not Detected.
Underlined are the last dilutions showing 100 % detection rates in the replicates. Each dilution was performed in duplicate and each duplicate tested in triplicate.
Replicates Detected Mean Ct Values
E Gene RdRp Orf1ab N Gene E Gene RdRp Orf1ab N Gene
Linear Dilution Series (10 fold) 1.00E-01 100 % 100 % 100 % 100 % 20.4 24.3 19.1 22.9
1.00E-02 100 % 100 % 100 % 100 % 23.5 27.3 22.9 25.8
1.00E-03 100 % 100 % 100 % 100 % 27.2 30.9 27.1 28.9
1.00E-04 100 % 100 % 100 % 100 % 30.6 34.5 30.8 31.7
1.00E-05 100 % 66 % 100 % 66 % 34.5 36.5 33.9 36.0
1.00E-06 66 % N.D. 66 % N.D. 38.2 N.D. 37.3 N.D.
1.00E-07 33% N.D. N.D. N.D. 39.1 N.D. N.D. N.D.
1.00E-08 N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D.
A. Bosworth, et al. Journal of Clinical Virology 128 (2020) 104469
2
with an overall SARS-2-CoV detection rate of 53/1230. A detection
frequency of 15 % (37/258) was found in cases where symptoms were
in keeping with COVID-19 diagnosis. Sixteen of 1025 (1.6 %) HCW with
no compatible symptoms and defined as asymptomatic had detectable
levels of viral RNA in their throat swabs.
Saliva was collected from 525 of the same HCW cohort as part of a
prevalence study of asymptomatic viral shedding. Fifteen oral fluid
samples from subjects with positive results by throat swab, were tested
using the VIASURE, of which five were positive. The Ct values were
lower (by approximately 3–5 Ct) compared to results on the subject’s
throat swab, suggesting a higher viral load in saliva. Interestingly,
follow-up of these asymptomatic HCW whose saliva specimens were
positive indicated that they later developed symptoms compatible with
COVID-19 disease. It is unclear however whether patients were truly
asymptomatic at the time of sampling, or possibly overlooked mild
symptoms; as they were not formally clinically assessed. Therefore,
saliva may represent a specimen type that can provide a more un-
ambiguous indicator of potential infectivity, removing the equivocality
of low-level positive throat swab results.
The capacity to rapidly deploy extra laboratory capabilities to
support surges in diagnostic testing workload, or to support the de-
velopment of testing infrastructure in rural and remote areas, will be
essential to controlling the current SARS-CoV-2 pandemic.
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Fig. 1. Linear dilution series was performed on extracted RNA derived from pooled throat swabs with detectable SARS-CoV-2 RNA. Data from linear dilution series in
the VIASURE in triplicate was compared to the results obtained with the E-gene (WHO) assay in a pairwise comparison.
Fig. 2. Analysis of reproducibility testing data using positive control specimens
(n = 10) tested in triplicate on the E gene, RDRP WHO assays compared to the
N and Orf1ab VIASURE targets. Standard deviation is calculated for variation
from the mean. The mean is given as a large red marker on the chart. The X-axis
indicates Ct values obtained in each assay for comparison.
Table 2
Clinical sensitivity of the VIASURE qRT-PCR Kit for detection of SARS-CoV-2 as determined in comparative analysis in the University of Birmingham and Queen
Elizabeth Hospital. Two commercial assays were used for comparison, the Altona qRT-PCR assay (n = 94) and the Abbott m2000 qRT-PCR assay (n = 26).
Queen Elizabeth Hospital RT-PCRs
Altona Assay Abbott Assay
Positive Negative Total Positive Negative Total
University of Birmingham VIASURE qRT-PCR Positive 48 1 49 10 0 10
Negative 0 42 42 0 16 16
Indeterminate 0 3 3 0 0 0
Totals 48 46 94 10 16 26
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